GLP1R and type 2 diabetes mellitus: For example, in patients with type 2 diabetes, weight loss (average of 15%) as a result of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) was found to lower the risk of HF hospitalization by 9% (HR: 0.91, 95% CI: 0.83–0.99; p = 0.028) according to a meta-analysis of seven randomized controlled trials [57].